The Future of Big Pharma

Friday, July 10, 2015 10:00 AM EST - 11:00 AM EST

Big Pharma continues to adapt to declining pipeline productivity, generic and biosimilar incursions, and pricing pressures. M&A activity has been buoyed by attractive financial conditions as companies compete for coveted assets in growth areas such as oncology in a bid to secure long-term revenues.

In spite of these challenges, big pharma is still expected to add $60 billion in revenues, according to Datamonitor Healthcare's "2015 Big Pharma Outlook" report.

Join us on Friday, July 10th at 10am EST for "The Future of Big Pharma", an Informa Pharma roundtable that will discuss and debate the data and analyses in this new report and bring new insights into the mix. Our Global Director of Content and all round industry expert, Mike Ward, will chair the live roundtable.

Discussion will be focused around 3 topics:

• The Outlook for Big Pharma
• Winners & Losers
• Threats & Opportunities

Hosted By:

Mike Ward

Global Director of Content
Informa Pharma

Panelists:

Armando Uribe

Financial Analyst
BioMedTracker

Ali Al-Bazergan

Sr. Company Analyst
Datamonitor Healthcare

Eleanor Malone

Editor
SCRIP Intelligence